822 related articles for article (PubMed ID: 31234870)
21. A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.
Wu Y; Peng Z; Gu S; Wang H; Xiang W
Comput Math Methods Med; 2022; 2022():2558548. PubMed ID: 35186111
[TBL] [Abstract][Full Text] [Related]
22. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
[TBL] [Abstract][Full Text] [Related]
23. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of a risk signature based on extracellular matrix-related genes in gliomas.
Liu J; Li G
Medicine (Baltimore); 2021 Apr; 100(16):e25603. PubMed ID: 33879726
[TBL] [Abstract][Full Text] [Related]
25. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
26.
Hu Z; Qu S
Front Immunol; 2021; 12():683572. PubMed ID: 34267752
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of the NLRC4 inflammasome contributes to poor prognosis in glioma patients.
Lim J; Kim MJ; Park Y; Ahn JW; Hwang SJ; Moon JS; Cho KG; Kwack K
Sci Rep; 2019 May; 9(1):7895. PubMed ID: 31133717
[TBL] [Abstract][Full Text] [Related]
28. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
29. Identification of FABP7 as a Potential Biomarker for Predicting Prognosis and Antiangiogenic Drug Efficacy of Glioma.
Hou L; Zhou H; Wang Y; Liu J; Zhang D; Li Y; Xue X
Dis Markers; 2022; 2022():2091791. PubMed ID: 35783014
[TBL] [Abstract][Full Text] [Related]
30. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
31. RGS16 promotes glioma progression and serves as a prognostic factor.
Huang R; Li G; Zhao Z; Zeng F; Zhang K; Liu Y; Wang K; Hu H
CNS Neurosci Ther; 2020 Aug; 26(8):791-803. PubMed ID: 32319728
[TBL] [Abstract][Full Text] [Related]
32. A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration.
Zhang M; Cheng Y; Xue Z; Sun Q; Zhang J
BMC Cancer; 2021 Dec; 21(1):1311. PubMed ID: 34876094
[TBL] [Abstract][Full Text] [Related]
33. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
34. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.
Chai R; Zhang K; Wang K; Li G; Huang R; Zhao Z; Liu Y; Chen J
J Cancer Res Clin Oncol; 2018 Mar; 144(3):439-447. PubMed ID: 29299749
[TBL] [Abstract][Full Text] [Related]
35. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.
Xu H; Chai S; Wang Y; Wang J; Xiao D; Li J; Xiong N
CNS Neurosci Ther; 2020 Aug; 26(8):804-814. PubMed ID: 32678519
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of GINS4 is associated with poor prognosis and survival in glioma patients.
Liu B; Liu Z; Wang Y; Lian X; Han Z; Cheng X; Zhu Y; Liu R; Zhao Y; Gao Y
Mol Med; 2021 Sep; 27(1):117. PubMed ID: 34556022
[TBL] [Abstract][Full Text] [Related]
37. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
38. Interferon regulatory factor transcript levels correlate with clinical outcomes in human glioma.
Lei J; Zhou MH; Zhang FC; Wu K; Liu SW; Niu HQ
Aging (Albany NY); 2021 Apr; 13(8):12086-12098. PubMed ID: 33902005
[TBL] [Abstract][Full Text] [Related]
39. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
[TBL] [Abstract][Full Text] [Related]
40. EPHB2 as a key mediator of glioma progression: Insights from microenvironmental receptor ligand-related prognostic gene signature.
Tan L; Zhou J; Nie Z; Li D; Wang B
Genomics; 2024 May; 116(3):110799. PubMed ID: 38286348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
